Skip to Main content Skip to Navigation
Journal articles

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

Abstract : Tyrosine kinase inhibitor (TKI)-based targeted therapy has significantly modified the outcome for patients with chronic myeloid leukemia (CML) in chronic phase. However, resistance remains a major concern in blastic phase of CML and in Philadelphia chromosome positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). Second- and third-generation TKIs have been developed to overcome resistance to first generation drugs, but selecting the appropriate drug has become a challenge. Various tests are available to determine a patient’s disease status in CML including the mechanisms of resistance when involved, but clinical experience is limited in ALL, especially those with poorly defined ABL1 rearrangements. Here, we report a case of ALL associated with a t(1;9)(q24;q34) RCSD1-ABL1 rearrangement. We show how ex vivo drug response profiling (DRP) may help choose among various therapeutic options.
Document type :
Journal articles
Complete list of metadatas

Cited literature [11 references]  Display  Hide  Download

https://hal-amu.archives-ouvertes.fr/hal-01218497
Contributor : Administrateur Hal Amu <>
Submitted on : Wednesday, October 21, 2015 - 12:09:09 PM
Last modification on : Thursday, December 20, 2018 - 12:08:02 PM

Files

bcj201513a (1).pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Y Collette, Thomas Prébet, A. Goubard, José Adelaïde, R Castellano, et al.. Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Blood Cancer Journal, Nature Publishing Group, 2015, 5 (e292), ⟨10.1038/bcj.2015.13⟩. ⟨hal-01218497⟩

Share

Metrics

Record views

154

Files downloads

388